Description
Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel.html" class="link-product" target="_blank"> Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer.
Cat.No
A882
Name
Navicixizumab
Chemical Properties
CAS
1638338-43-8
Synonyms
Navicixizumab;OMP 305B83;Research Grade Navicixizumab (DHJ65303);Research Grade Navicixizumab (DHJ65303);Research Grade Navicixizumab (DHJ65303);Research Grade Navicixizumab (DHJ65303)
pH value
Corresponds to reference standard: PASS
Non-reduced CE-SDS
>95%
SEC-HPLC
>95%
Isoelectric Point
Corresponds to reference standard
Bacterial Endotoxins Test
Residual Proteins of Host Cell
Exogenous Residual DNA
Residual protein A
Biological Activity
Osmolality
Corresponds to reference standard: PASS
Peptide mapping
Corresponds to reference standard: PASS
N-terminal sequence
Corresponds to reference standard: PASS
References
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
Tel: +86-21-58447131Fax: +86-21-61642470Email:
Website:
